Get the Stockscreener App
5.33
1.11%
-0.06
Leonabio Inc stock is traded at $5.33, with a volume of 20,428.
It is down -1.11% in the last 24 hours and down -26.38% over the past month.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
See More
Previous Close:
$5.39
Open:
$5.41
24h Volume:
20,428
Relative Volume:
0.03
Market Cap:
$50.22M
Revenue:
Net Income/Loss:
$-129.41M
P/E Ratio:
-0.2212
EPS:
-24.0922
Net Cash Flow:
$-51.97M
1W Performance:
-7.30%
1M Performance:
-26.38%
6M Performance:
-43.78%
1Y Performance:
+0.00%
1-Day Range:
$4.9101
$5.44
1-Week Range:
$5.25
$6.72
52-Week Range:
$2.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
Name
Leonabio Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
5.33 | 50.22M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
508.89 | 128.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.19 | 95.10B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.60 | 82.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.78 | 53.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-26 | Upgrade | Citizens | Mkt Perform → Mkt Outperform |
| May-27-26 | Initiated | Piper Sandler | Overweight |
| Feb-26-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-19-26 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Leonabio Inc Stock (LONA) Latest News
LeonaBio at Cantor healthcare conference: bets on ESR1 combo edge By Investing.com - Investing.com South Africa
LeonaBio at Cantor healthcare conference: bets on ESR1 combo edge By Investing.com - Investing.com India
LeonaBio at Cantor healthcare conference: bets on ESR1 combo edge By Investing.com - Investing.com Canada
LeonaBio (LONA) Stock Analysis Report | Financials & Insights - Benzinga España
LeonaBio to Participate in Cantor Global Healthcare Conference 2026 - Yahoo Finance
A drug developer's New York fireside chat is set for Sept. 11 - Stock Titan
Perceptive Advisors LLC Expands LeonaBio Inc (LONA) Stake in Str - GuruFocus
Sermonix Pharmaceuticals Discloses Investment at LeonaBio, Inc. with 36.9% Stake - TradingView
Prefunded warrants drive Sermonix-led LeonaBio (LONA) share shakeup - Stock Titan
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
LeonaBio Reaches Key Phase 3 Enrollment Milestone - TipRanks
Perceptive's LeonaBio (NASDAQ: LONA) stake nears its ownership limit - Stock Titan
Anders Hove reports new passive stake in LeonaBio (LONA) - Stock Titan
LONA Maintained by Mizuho -- Price Target Lowered to $15.00 - GuruFocus
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com Nigeria
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com South Africa
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com India
Mizuho lowers LeonaBio stock price target on higher OpEx - Investing.com
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com Canada
Mizuho lowers LeonaBio stock price target on higher OpEx - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), LeonaBio (LONA) - The Globe and Mail
LeonaBio Reports Narrower Quarter Loss as Trial Progresses - sekbernews.id
LeonaBio: ELAINE-3 Enrollment Reaches 495 Of About 600 Patients As Up To $146 Million Of Warrant Proceeds Could Support Upcoming Milestones - Pulse 2.0
LeonaBio (LONA) Market Close: Closes 3.19% Higher at $7.96 at the Close; Level Check: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotLow Volatility Picks - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Elicio Therapeutics (ELTX), EyePoint Pharmaceuticals (EYPT) and LeonaBio (LONA) - The Globe and Mail
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio Inc. (LONA) Climbs 2.84% to $8.19 as Biotech Buyers Target $8.60 ResistanceWedge Breakout - vinanet.vn
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LONA Maintained by Citizens -- Price Target Lowered to $17.00 - GuruFocus
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances - Yahoo Finance
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Nigeria
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Australia
LeonaBio beats second quarter loss estimates - Investing.com
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Canada
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio beats second quarter loss estimates - Investing.com
LeonaBio Inc (LONA) Q2 Results Highlight Challenges for Valuatio - GuruFocus
Citizens lowers LeonaBio stock price target to $17 on valuation By Investing.com - Investing.com Canada
LeonaBio Inc. (LONA) Climbs 2.84% to $8.19 as Biotech Buyers Target $8.60 ResistanceEarnings Quality Factor - dars.gov.et
LeonaBio Q2 Results: EPS beats estimate, losses narrow 55% YoY - scanx.trade
LeonaBio Narrows Q2 Loss - marketscreener.com
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
LeonaBio (LONA) loss widens as cash burn rises and going concern risk emerges - Stock Titan
LeonaBio Q2 net loss widens on higher R&D spending - TradingView
LeonaBio Posts $19.0 Million Q2 Loss as ELAINE-3 Enrollment Advances - Quiver Quantitative
LeonaBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
LeonaBio, Inc. (NASDAQ: LONA) Share Price, LONA Stock News, LONA Share Price & Updates - Kalkine
LeonaBio, Inc. (NASDAQ: LONA) Share Price, LONA Stock News, LONA Share Price & Updates - kalkine.ca
Leonabio Inc Stock (LONA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Leonabio Inc Stock (LONA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
| Mark James Litton | Officer |
Mar 04 '26 |
Proposed Sale |
5.36 |
5,156 |
27,662 |
0 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
3.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):